Formoterol Fumarate/Glycopyrrolate

富马酸福莫特罗/格隆溴铵

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFormoterol Fumarate/Glycopyrrolate
Drug Alias NameGlycopyrrolate/formoterol fumarate格隆溴铵/富马酸福莫特罗格隆溴铵福莫特罗glycopyrrolate and formoterol fumarateFormoterol Fumarate/Glycopyrronium Bromide +[8] 
ClassificationSmall molecules
Mechanisms of ActionMuscarinic acetylcholine receptor antagonistsBeta-2 adrenergic receptor agonists
TargetsMuscarinic acetylcholine receptorBeta-2 adrenergic receptor
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryUnited States
Original Approved Date2016/04/25
Country/TerritoryBelgiumBulgariaCanada +[14] 
CombinationsYes Formoterol FumarateGlycopyrronium Bromide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca AbRecipharm Hc Ltd
Inactive CompaniesPearl Therapeutics IncAstrazeneca PlcFisons Ltd +[4] 
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeR03AL07
Related LinksKEGG